Katherine K. Matthay

39.3k citations

302 papers · 26.5k indexed · 10 hit papers · h-index 85

Neurology top 0.01%
Molecular Biology top 0.2%
Cancer Research top 0.05%
Oncology top 0.5%
Surgery top 0.5%

Co-authors: Robert C. Seeger John M. Maris Wendy B. London Hiroyuki Shimada Daniel O. Stram Robert B. Gerbing Susan L. Cohn C. Patrick Reynolds
Topics: Neuroblastoma Research and Treatments (225 papers)Cancer, Hypoxia, and Metabolism (106 papers)Cancer therapeutics and mechanisms (79 papers)
Cited by: Neurology Cancer Research Genetics
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Journal of Clinical Investigation
Partner nations: United States Switzerland France

In The Last Decade

Katherine K. Matthay

298 papers receiving 26.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

1999 1.4k citations Katherine K. Matthay, Judith G. Villablanca et al. profile →
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

1991 1.3k citations Demetrios Papahadjopoulos, Katherine K. Matthay et al. profile →
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

2008 1.3k citations Susan L. Cohn, Andrew D.J. Pearson et al. Journal of Clinical Oncology profile →
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

2010 1.2k citations Alice L. Yu, Andrew L. Gilman et al. profile →
Neuroblastoma

2016 897 citations Katherine K. Matthay, John M. Maris et al. profile →
The International Neuroblastoma Pathology Classification (the Shimada system)

1999 739 citations Hiroyuki Shimada, Daniel O. Stram et al. Cancer profile →
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report

2008 678 citations Tom Monclair, Garrett M. Brodeur et al. Journal of Clinical Oncology profile →
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

2009 621 citations Katherine K. Matthay, C. Patrick Reynolds et al. Journal of Clinical Oncology profile →
Advances in Risk Classification and Treatment Strategies for Neuroblastoma

2015 611 citations Navin Pinto, Katherine K. Matthay et al. Journal of Clinical Oncology profile →
Advancing therapy for neuroblastoma

2022 203 citations Katherine K. Matthay et al. profile →

Peers

Countries citing papers authored by Katherine K. Matthay

Since Specialization

Citations

This map shows the geographic impact of Katherine K. Matthay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine K. Matthay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine K. Matthay more than expected).

Fields of papers citing papers by Katherine K. Matthay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine K. Matthay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine K. Matthay. The network helps show where Katherine K. Matthay may publish in the future.

Co-authorship network of co-authors of Katherine K. Matthay

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine K. Matthay. A scholar is included among the top collaborators of Katherine K. Matthay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine K. Matthay. Katherine K. Matthay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to ¹³¹I‐MIBG in patients with relapsed/refractory neuroblastoma 2023 ·Pediatric Blood & Cancer ·Vandana Batra,Ajami Gikandi,Bruce Pawel,Daniel Martínez,Meaghan Granger,Araz Marachelian,Julie R. Park,John M. Maris,Kieuhoa T. Vo,Katherine K. Matthay,Steven G. DuBois	2
2	Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project 2022 ·Pediatric Blood & Cancer ·Kieuhoa T. Vo,Steven G. DuBois,John Neuhaus,Steve Braunstein,Brent R. Weil,Arlene Naranjo,Sabine Irtan,Julia Balaguer,Katherine K. Matthay	5
3	Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource‐limited countries 2022 ·Pediatric Blood & Cancer ·Katherine K. Matthay,(unknown),(unknown),Mohammed Khattab,Shui Yen Soh,(unknown),Ana Patricia Alcasabas,Mohamed Fawzy,Raya Saab,Muhammad Saghir Khan,Khalil Ghandour,Guillermo Chantada,Nehal S. Parikh,Lawrence Faulkner,Catherine G. Lam,Scott C. Howard	6
4	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 2021 ·Clinical Cancer Research ·Alice L. Yu,Andrew L. Gilman,M. Fevzi Özkaynak,Arlene Naranjo,Mitchell B. Diccianni,Jacek Gan,Jacquelyn A. Hank,Ayse Batova,Wendy B. London,Sheena C. Tenney,Malcolm A. Smith,Barry L. Shulkin,Marguerite T. Parisi,Katherine K. Matthay,Susan L. Cohn,John M. Maris,Rochelle Bagatell,Julie R. Park,Paul M. Sondel	132
5	Anatomic patterns of relapse and progression following treatment with ¹³¹I‐MIBG in relapsed or refractory neuroblastoma 2021 ·Pediatric Blood & Cancer ·(unknown),Alexei L. Polishchuk,Randall A. Hawkins,Steve Braunstein,Katherine K. Matthay,Steven G. DuBois,Daphne A. Haas‐Kogan	1
6	A safety and feasibility trial of ¹³¹I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study 2021 ·Pediatric Blood & Cancer ·Brian Weiss,Gregory A. Yanik,Arlene Naranjo,Fan F. Zhang,Wendy Fitzgerald,Barry L. Shulkin,Marguerite T. Parisi,Heidi V. Russell,Stephan A. Grupp,Luke Pater,Peter Mattei,Yaël P. Mossé,Hollie Lai,Jason A. Jarzembowski,Hiroyuki Shimada,Judith G. Villablanca,Roger Giller,Rochelle Bagatell,Julie R. Park,Katherine K. Matthay	23
7	Role of the extent of prophylactic regional lymph node radiotherapy on survival in high‐risk neuroblastoma: A report from the COG A3973 study 2019 ·Pediatric Blood & Cancer ·Steve Braunstein,Wendy B. London,Susan G. Kreissman,Judith G. Villablanca,Andrew M. Davidoff,Kenneth B. DeSantes,Robert P. Castleberry,Kevin A. Murray,Lisa Diller,Katherine K. Matthay,Susan L. Cohn,Barry L. Shulkin,Daniel von Allmen,Marguerite T. Parisi,Collin Van Ryn,Julie R. Park,Michael P. LaQuaglia,Daphne A. Haas‐Kogan	9
8	Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project 2019 ·Pediatric Blood & Cancer ·Kevin Campbell,Derek Shyr,Rochelle Bagatell,Matthias Fischer,Akira Nakagawara,Adela Cañete,Garrett M. Brodeur,Katherine K. Matthay,Wendy B. London,Steven G. DuBois	25
9	Predictors of response, progression‐free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high‐risk neuroblastoma 2018 ·Pediatric Blood & Cancer ·Judith G. Villablanca,Lingyun Ji,(unknown),Araz Marachelian,Hiroyuki Shimada,Randall A. Hawkins,Miguel Hernandez Pampaloni,Hollie Lai,Fariba Goodarzian,Richard Sposto,Julie R. Park,Katherine K. Matthay	7
10	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial 2018 ·Pediatric Blood & Cancer ·Navin Pinto,Steven G. DuBois,Araz Marachelian,Scott J. Diede,Agne Taraseviciute,Julia Glade Bender,Denice Tsao‐Wei,Susan Groshen,Joel M. Reid,Daphne A. Haas‐Kogan,C. Patrick Reynolds,Min H. Kang,Meredith S. Irwin,Margaret E. Macy,Judith G. Villablanca,Katherine K. Matthay,Julie R. Park	27
11	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group 2017 ·Cancer ·Kevin Campbell,Julie M. Gastier‐Foster,(unknown),Arlene Naranjo,Collin Van Ryn,Rochelle Bagatell,Katherine K. Matthay,Wendy B. London,Meredith S. Irwin,(unknown),Meaghan Granger,Michael D. Hogarty,Julie R. Park,Steven G. DuBois	95
12	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group 2016 ·Clinical Cancer Research ·Kieuhoa T. Vo,(unknown),C. Lorrie Epling,Elizabeth Sinclair,Douglas S. Hawkins,Holcombe E. Grier,Katherine A. Janeway,Phillip Barnette,(unknown),Mark Krailo,Donald A. Barkauskas,Katherine K. Matthay,Richard B. Womer,Richard Görlick,Stephen L. Lessnick,Crystal L. Mackall,Steven G. DuBois	17
13	SIOP‐PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low‐ and middle‐income settings 2015 ·Pediatric Blood & Cancer ·Nehal S. Parikh,Scott C. Howard,Guillermo Chantada,Trijn Israëls,Mohammed Khattab,Patricia Alcasabas,Catherine G. Lam,Lawrence Faulkner,Julie R. Park,Wendy B. London,Katherine K. Matthay	71
14	Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving¹³¹I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma 2015 ·Pediatric Blood & Cancer ·Jean S. Lee,Rebecca Wu,(unknown),Steven G. DuBois,Katherine K. Matthay,(unknown),Randall A. Hawkins,Arup Roy‐Burman	3
15	Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma In Vitro and In Vivo Model Systems 2011 ·Clinical Cancer Research ·Swati S. More,Melissa Itsara,Xiao-Dong Yang,Ethan G. Geier,(unknown),Youngho Seo,Henry F. VanBrocklin,William A. Weiss,Sabine Mueller,Daphne A. Haas‐Kogan,Steven G. DuBois,Katherine K. Matthay,Kathleen M. Giacomini	51
16	Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age 2011 ·Journal of Clinical Oncology ·(unknown),Wendy B. London,Mary Lou Schmidt,Steven G. DuBois,Tom Monclair,Akira Nakagawara,Bruno De Bernardi,Peter F. Ambros,Andrew D.J. Pearson,Susan L. Cohn,Katherine K. Matthay	48
17	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project 2011 ·Journal of Clinical Oncology ·Wendy B. London,Victoria Castel,Tom Monclair,Peter F. Ambros,Andrew D.J. Pearson,Susan L. Cohn,Frank Berthold,Akira Nakagawara,Ruth Ladenstein,Tomoko Iehara,Katherine K. Matthay	229
18	IS ADJUVANT THERAPY EVER WARRANTED IN LOCALIZED NEUROBLASTOMA 2000 ·The American journal of pediatric hematology/oncology ·Katherine K. Matthay,Daniel O. Stram	5
19	Metastatic Sites in Stage IV and IVS Neuroblastoma Correlate With Age, Tumor Biology, and Survival 1999 ·Journal of Pediatric Hematology/Oncology ·Steven G. DuBois,(unknown),John N. Lukens,Garrett M. Brodeur,Robert C. Seeger,James B. Atkinson,Gerald M. Haase,Charles T. Black,Carlos A. Pérez,Hiroyuki Shimada,Robert B. Gerbing,Daniel O. Stram,Katherine K. Matthay	314
20	Specific enhancement of drug delivery to AKR lymphoma by antibody-targeted small unilamellar vesicles. 1984 ·PubMed ·Katherine K. Matthay,Timothy D. Heath,Demetrios Papahadjopoulos	61

About Katherine K. Matthay

Katherine K. Matthay is a scholar working on Neurology, Cancer Research and Genetics, having authored 302 papers that have together received 26.5k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (225 papers), Cancer, Hypoxia, and Metabolism (106 papers) and Cancer therapeutics and mechanisms (79 papers). The work is most often cited by research in Neurology (19.0k citations), Cancer Research (8.0k citations) and Genetics (2.6k citations). Katherine K. Matthay has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include Robert C. Seeger, John M. Maris, Wendy B. London, Hiroyuki Shimada, Daniel O. Stram, Robert B. Gerbing, Susan L. Cohn, C. Patrick Reynolds, Judith G. Villablanca and Garrett M. Brodeur. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact